Haemonetics Corporation (NYSE:HAE) Director Pedro P. Granadillo sold 7,118 shares of the stock in a transaction dated Friday, December 1st. The stock was sold at an average price of $57.06, for a total value of $406,153.08. Following the sale, the director now owns 31,663 shares of the company’s stock, valued at $1,806,690.78. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.
Shares of Haemonetics Corporation (NYSE:HAE) opened at $57.36 on Wednesday. The company has a current ratio of 2.17, a quick ratio of 1.51 and a debt-to-equity ratio of 0.22. Haemonetics Corporation has a 1-year low of $36.44 and a 1-year high of $58.99. The firm has a market capitalization of $2,975.78, a PE ratio of 34.56, a price-to-earnings-growth ratio of 4.23 and a beta of 0.99.
Haemonetics (NYSE:HAE) last issued its earnings results on Tuesday, November 7th. The medical instruments supplier reported $0.48 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.41 by $0.07. The company had revenue of $225.40 million during the quarter, compared to the consensus estimate of $219.12 million. Haemonetics had a return on equity of 11.16% and a net margin of 0.50%. The firm’s revenue for the quarter was up 2.3% compared to the same quarter last year. During the same period last year, the business posted $0.38 EPS. sell-side analysts predict that Haemonetics Corporation will post 1.7 earnings per share for the current year.
A number of brokerages have weighed in on HAE. Zacks Investment Research downgraded Haemonetics from a “buy” rating to a “hold” rating in a report on Monday, November 20th. Morgan Stanley increased their price target on Haemonetics from $43.00 to $51.00 and gave the stock an “equal weight” rating in a report on Thursday, November 9th. Craig Hallum reiterated a “hold” rating and set a $50.00 price target (up from $40.00) on shares of Haemonetics in a report on Wednesday, November 8th. Barrington Research increased their price target on Haemonetics from $48.00 to $57.00 and gave the stock an “outperform” rating in a report on Wednesday, November 8th. Finally, BidaskClub upgraded Haemonetics from a “strong sell” rating to a “sell” rating in a report on Tuesday, August 8th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and three have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average target price of $53.33.
Institutional investors and hedge funds have recently modified their holdings of the company. Shine Investment Advisory Services Inc. acquired a new stake in shares of Haemonetics in the 2nd quarter valued at about $132,000. Riverhead Capital Management LLC grew its stake in shares of Haemonetics by 79.3% in the 2nd quarter. Riverhead Capital Management LLC now owns 3,407 shares of the medical instruments supplier’s stock valued at $135,000 after buying an additional 1,507 shares during the period. Pacad Investment Ltd. acquired a new stake in shares of Haemonetics in the 2nd quarter valued at about $174,000. Shelton Capital Management acquired a new stake in shares of Haemonetics in the 2nd quarter valued at about $204,000. Finally, Cubist Systematic Strategies LLC acquired a new stake in shares of Haemonetics in the 2nd quarter valued at about $260,000.
TRADEMARK VIOLATION WARNING: “Pedro P. Granadillo Sells 7,118 Shares of Haemonetics Corporation (HAE) Stock” was originally posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this report can be accessed at https://ledgergazette.com/2017/12/06/pedro-p-granadillo-sells-7118-shares-of-haemonetics-corporation-hae-stock.html.
Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company’s segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals.
Receive News & Ratings for Haemonetics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.